Huerta RS, Rubio GAF, Flores AG

Language: Spanish
References: 25
Page: 87-94
PDF size: 315.33 Kb.

ABSTRACT

Background: The End Renal Disease is increasing in all the world. In Mexico, 95% of end renal disease patients receive treatment with peritoneal dialysis. Peritonitis in DP remains a major cause of technique failure and transfer of patients to hemodialysis. Our objetive is to examine hypoalbuminemia as risk factor for peritonitis in patientes with ERD under peritoneal dialysis and to identify other variables as risk factors too.
Materials and methods: We included patients with ERD under DP in three hospitals of México City, between March 2007 and frebuary 2009. Those were split in two groups (with and without peritonits). The data recorded based on files were seric albumin level, age, sex, cause of ERD, duration of PD, previous cateter history, smoking, anemia and colesterol. Both groups were comparated by x² test, t student test, odds ratio and confidence intervals.
Results: We analized 60 patients, 30 in the peritonitis group and 30 in the no peritonitis group. No differences found in most demographics variables as edad, sex, cause of ERD, etc; we no found neither differences in the laboratory variables as anemia, colesterol and plaquetas. There were differences in seric albumin level and previous peritonitis history among groups (p‹ .05); of these, hypoalbuminemia only showed risk factor for peritonitis with OR 16 (CI 4.5 – 56).
Conclusion: The patients in DP with hypoalbuminemia several (‹ 2.2g/dL ) have higher risk for developed peritontiis (16 more times) than patiens with seric albumine over 2.2g/dL.

REFERENCES

1. Saxena R, West Ch. Peritoneal Dialysis: A Primary Care Perspective. J Am Board Fam Med 2006;19:380-389.

2. Hernández LS, Macas AA, Méndez FJ, Amato D, Paniagua R. Epiemiologic and Demographic aspects of perytonial dialysis in Mexico. Perit Dial Inter 1996;16:362-365.

3. National Kidney Foundation K/DOQI. Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Kidney disease outcome quality initiative. Am J Kidney Dis 2002;39:S1-246.

4. Remuzzi G, SchiepattiI A, Ruggenenti P. Nephrophaty In Patients With Type 2 Diabetes. N Engl J Med 2002;346:1145-1151.

5. Pastan S, Bailey J. Dialysis Therapy. N Engl J Med 1998;338:1428-1437.

6. Piraino B. Peritonitis as a Complication of Peritoneal Dialysis. J Am Soc Nephrol 1998;9:1956-1964.

7. Kang SW, Kwon KH, Noh HI, et al. Serum albumin as a predictor of morbidity and mortality in continuous ambulatory peritoneal dialysis patients: Single center experiences in over 700 patients. J Am Soc Nephrol 1996;7:1450-1455.

8. Avram MM, Goldwasser P, Erroa M, Fein PA. Predictors of survival in continuous ambulatory peritoneal dialysis patients: The importance of preabbumin and other nutritional and metabolic markers. Am J Kidney Dis 1994;23:91-98.

9. Kaplan AA, Halley SE, Lapkin RA, Graeber CW. Dialysate protein losses with bleach processed polysulphone diabyzens. Kidney mt 1995;47:573-578.

10. Han SH, Lee SC, Ahn SV. Reduced residual renal function is a risk of peritonitis in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant 2007;22: 2653-2658.

11. Krishnan M, Thodis E, Ikonomopoulos D, et al. Predictors of outcoms following bacterial peritonitis in peritoneal dialysis. Perit Dial Int 2002;22:573-581.

12. Chow KM, Szeto CC, Leung CB, et al. A risk analysis of continuous ambulatory peritoneal dialysis-related peritonitis. Perit Dial Int 2005;25:374-379.

13. Oo TN, Roberts TL, Collins AJ. A comparison of peritonitis rates from the United States renal data system database: CAPD versus continuous cycling peritoneal dialysis patients. Am J Kidney Dis 2004;45: 372-380.

14. Korbert SM, Vonesh EF, Firanek CA. A retrospective assessment of risk factors for peritonitis among an urban CAPD population. Perit Dial Int 1993;13:126-131.

15. Gulati S, Stephens D, Balfe JA, et al. Is hipoalbuminemia in children in continuous peritoneal dialysis a risk for technic failure. Kid Inter 2001;59:2361-2367.

16. Meza MJ, García E, Mendoza L. Factores de riesgo de peritonitis recurrente en pacientes pediátricos con insuficiencia renal crónica en diálisis peritoneal continua ambulatoria. Enf Inf Microbiol 2006;26:46-51.

17. Struijk DG, Krediet RT, Koomen GCM, Boeschoten EW, Arisz L. The effect of serum albumin at the start of continuous ambulatory peritoneal dialysis treatment on patient survival. Perit Dial Int 1994;14:121-126.

18. Holley JL, Bernardini J, Perlmutter JA, et al. A comparison of infection rates among older and younger patients on continuous peritoneal dialysis. Perit Dial Int 1994;14:66-69.

19. De Vecchi AF, Maccario M, Braga M, et al. Peritoneal dialysis in nondiabetic patients older than 70 years: comparison with patients aged 40 to 60 years. Am J Kidney Dis 1998;31:479-490.

20. Blake PG, Flowerdew G, Blake RM, Oreopoulos DG. Serum albumin in patients on continuous ambulatory peritoneal dialysis: Predictors and correlations with outcomes. J Am Soc Nephrol 1993;3:1501-1507.

21. Young GA, Young JB, Young SM, et al. Nutrition and delayed hypersensitivity during continuous ambulatory peritoneal dialysis in relation to peritonitis. Nephron 1986;43:177-186.

22. Kaysen GA. Biological Basis of Hypoalbuminemia in ESRD. J Am Soc Nephrol 1998;9:2368-2376.

23. Kaysen GA, Yeun I, Depner T. Albumin synthesis, catabolism and distribution in dialysis patients. Miner Electrolyte Metab 1997;23:218-224.

24. Ikizler TA, Wingard RL, Hakim RM. Interventions to treat malnutrition in dialysis patients: The role of the dose of dialysis, intradialytic parenteral nutrition, and growth hormone. Am J Kidney Dis 1999;26:256-265.

25. Gómez-Gómez M, Danglot-Banck C. El estudio de casos y controles: su diseño, análisis e interpretación en investigación clínica. Rev Mex Ped 2003;70:257-263.